UBS initiates coverage on Visa (V) with a Neutral; Secular Story Still Intact, But Durbin Impacts Hit Growth
Tweet
Share
E-mailGet Alerts V Hot Sheet
Price: $371.04 +1.45%
Rating Summary:
45 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
45 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UBS initiates coverage on Visa (NYSE: V) with a Neutral rating. PT $124.
UBS analyst says, "With shares sitting at all-time highs (dollar value—not forward P/E), we think short-term outsize gains are far less likely now than 6-9 months ago. The multiple has recovered to near pre-Durbin Amendment levels, and V is again a “consensus long” Financial Tech name despite more difficult FY12 comps and Durbin-related strategic uncertainty. As such, we would not be buyers at this point in the cycle."
"Near-term�worries aside, we believe V remains an excellent company, and we view the model as strong and intact. Ownership data show the stock’s appeal has broadened considerably over time, as value and income-oriented investors have joined V’s traditional growth investor base—creating a more stable, long-term focused ownership base and a strong backstop for the shares."
To See Ratings Summary & History on V, Click Here
UBS analyst says, "With shares sitting at all-time highs (dollar value—not forward P/E), we think short-term outsize gains are far less likely now than 6-9 months ago. The multiple has recovered to near pre-Durbin Amendment levels, and V is again a “consensus long” Financial Tech name despite more difficult FY12 comps and Durbin-related strategic uncertainty. As such, we would not be buyers at this point in the cycle."
"Near-term�worries aside, we believe V remains an excellent company, and we view the model as strong and intact. Ownership data show the stock’s appeal has broadened considerably over time, as value and income-oriented investors have joined V’s traditional growth investor base—creating a more stable, long-term focused ownership base and a strong backstop for the shares."
To See Ratings Summary & History on V, Click Here
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DA Davidson Starts Everus (ECG) at Buy
- William Blair Starts Beta Bionics, Inc. (BBNX) at Market Perform
- William Blair Starts Tandem Diabetes Care (TNDM) at Outperform
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
